Application of pharmaceutical composition preparation in preparation of medicine for treating 2019-nCoV infected critical patient

A 2019-ncov and drug technology, applied in the field of medicine, can solve the problems of safety pending clinical research demonstration, complexity, time-consuming, etc., and achieve the effect of extensive pharmaceutical value, strong safety and good efficacy

Pending Publication Date: 2021-08-10
ALLIFE MEDICAL SCI & TECH CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is a complicated and time-consuming process to find a vaccine similar to the virus immunogen. At the same time, the safety of the vaccine as a new structure needs to be demonstrated by clinical research.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pharmaceutical composition preparation in preparation of medicine for treating 2019-nCoV infected critical patient
  • Application of pharmaceutical composition preparation in preparation of medicine for treating 2019-nCoV infected critical patient
  • Application of pharmaceutical composition preparation in preparation of medicine for treating 2019-nCoV infected critical patient

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Example 1: Construction of ACE2-His MSC

[0046] This embodiment builds ACE2-His MSC, comprises the following steps:

[0047] Step 1: Construction of lentivirus

[0048] Step 1.1: constructing the recombinant vector ACE2-his;

[0049] Step 1.2: Construct the lentiviral vector Plenti-ACE2-his;

[0050] Step 1.3: Lentiviral packaging;

[0051] Step 2: MSC Cell Culture Expansion

[0052] Take the fresh umbilical cord of a healthy newborn, wash the umbilical cord with PBS, remove the blood vessels, peel off the Wahrenheit tissue, and fully cut the remaining tissue to 1mm 3 size, add α-MEM medium, at 37°C, 5% CO 2 Cultivate in an incubator, and after the cells are confluent, digest and passage with 0.25% trypsin; add PBS to adjust the cell concentration to 1×10 6 / mL to obtain MSC cells.

[0053] Step 3: Infect the MSC cells obtained in step 2 with the lentivirus obtained in step 1, and then culture;

[0054] Step 4: Antibiotic screening to obtain stable cell lines; ...

Embodiment 2

[0056] Example 2: Construction of CAR-NK antiHis

[0057] The construction of CAR-NK antiHis in this embodiment includes the following steps:

[0058] Step 1: Construction of lentivirus

[0059] Step 1.1: Construction of the recombinant vector CAR-NK-anti-his;

[0060] Step 1.2: Construction of lentiviral vector Plenti-CAR-NK-anti-his;

[0061] Step 1.3: Lentiviral packaging;

[0062] Step 2: NK cell culture expansion

[0063] 200 mL of peripheral blood was drawn, NK cells were sorted, residual red blood cells were removed, and NK cells were expanded and cultured to obtain NK cells.

[0064] Step 3: Infect the NK cells obtained in step 2 with the lentivirus obtained in step 1, and then culture;

[0065] Step 4: Anti-his CAR-NK cells are collected and stored;

[0066] Step 5: incubation and detection of fluorescently labeled his antigen;

[0067] Step 6: Detection of anti-his CAR expression by RT-PCR.

[0068] Experimental results

[0069] Such as figure 1 As shown, N...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses an application of a pharmaceutical composition preparation in preparation of a medicine for treating a critical patient infected by 2019-nCoV, and belongs to the technical field of medicines. According to the application disclosed by the invention, the combination of the ACE-h i s MSC and the CAR-NK ant i Hi s is found for the first time and can be used for preparing the medicine for treating the severe patients infected by the 2019-nCoV, a new application field of the ACE-h i s MSC and the CAR-NK ant i Hi s is developed, a new medicine for treating the severe patients infected by the 2019-nCoV is also developed, and the application has positive pharmaceutical value and wide social significance.

Description

technical field [0001] The invention relates to the application of a drug combination preparation in the preparation of drugs for the treatment of severe patients infected with 2019-nCoV, belonging to the technical field of drugs. Background technique [0002] 2019 Novel Coronavirus (2019 Novel Coronavirus, referred to as 2019-nCoV) is a new strain of coronavirus discovered in humans in 2019. The clinical manifestations of infected patients are mainly fever, fatigue and dry cough, and a small number of patients are accompanied by nasal congestion, runny nose and diarrhea and other symptoms. Severe cases often develop dyspnea one week later, and critically ill patients may develop acute respiratory distress syndrome, septic shock, metabolic acidosis that is difficult to correct, and coagulation dysfunction. Some patients have mild onset symptoms, may have no fever, and mostly recover after a week. The prognosis of most patients is good, and a few patients are in critical co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/28A61K35/17A61P31/14C12N5/10C12N15/62C12N15/867
CPCA61K35/28A61K35/17A61P31/14C12N9/485C12N15/86C12N5/0665C12N5/0646C07K14/7051C07K16/18C12Y304/17023C12N2510/00C12N2740/15043C07K2319/21C07K2319/33
Inventor 顾雨春刘晓庆毛淦明
Owner ALLIFE MEDICAL SCI & TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap